IP Library › Granted Patent US 11,359,005
Granted Patent B2
US 11,359,005 · App. 16/498,675 · Granted Jun 14, 2022

Supramolecular high affinity protein-binding system for purification of biomacromolecules

Inventors: Honggang Cui (Lutherville, MD); Yi Li (Baltimore, MD); Xuankuo Xu (Boxborough, MA); Lye Lin Lock (Maynard, MA); Zhengjian Li (Sudbury, MA)
Assignees: THE JOHNS HOPKINS UNIVERSITY; BRISTOL-MYERS SQUIBB COMPANY
C07K16/065B01D15/3809B01J20/24B01J20/28023C07K14/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,359,005
App. No.
16/498,675
Granted
Jun 14, 2022
Kind
B2
Abstract

In certain embodiments, the present invention provides novel antibody purification methods and systems using a potentially simple and cost-efficient means. In some embodiments, customized Z-33 derived from Staphylococcus aureus Protein A is used to construct immuno-amphiphile molecules which can assemble into immunofibers in aqueous solution with bioactive epitopes on the surface and have IgG binding ability.

Claims (13)

1. An IgG binding immuno-amphiphile consisting of the amino acid sequence of SEQ ID NO: 1 conjugated at the N-terminus to a lauric acid moiety.

2. The IgG binding immuno-amphiphile of claim 1 , wherein a peptide portion of the IgG binding immuno-amphiphile has an α-helical conformation when in an aqueous solution at a pH between 2.8 to 7.4.

3. A conjugate of the IgG binding immuno-amphiphile of claim 1 with Rhodamine B.

4. A method for purification of an antibody or an Fc fusion protein, comprising the steps of:

dissolving the IgG binding immuno-amphiphile of claim 1 in an aqueous solution at physiological pH, and aging overnight to make it self-assemble into immunofibers (IFs);

mixing a sample containing an antibody or an Fc fusion protein with the IFs, and allowing the IFs to bind the Fc portion of the antibody or Fc fusion protein and form an immunofiber-antibody complex or immunofiber-Fc fusion protein complex in solution;

separating the immunofiber-antibody complex or the immunofiber-Fc fusion protein complex from the solution; and

dissociating the IFs from the antibody or Fc fusion protein and collecting the unbound antibody or Fc fusion protein.

5. The method of claim 4 , wherein the IFs are separated from the antibody or Fc fusion protein by lowering the pH to elution condition and filtration or microfiltration.

6. The method of claim 4 , wherein the IFs are separated from the antibody or Fc fusion protein by salt-induced precipitation and centrifugation.

7. The method of claim 4 , wherein the IFs are separated from the antibody or Fc fusion protein by diafiltration.

8. The method of claim 4 , wherein a peptide portion of the IgG binding immuno-amphiphile has an α-helical conformation when in an aqueous solution at a pH between 2.8 to 7.4.

9. The method of claim 4 , wherein the IgG binding immuno-amphiphile is conjugated to Rhodamine B.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: CUI, HONGGANG; LI, YI
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 051822/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: LI, ZHENGJIAN; XU, XUANKUO; LOCK, LYE LIN
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 051822/0421 →
Continuity (2)
Provisional Application 62478886 · Mar 30, 2017
Related Publication 20200062827A1 · Feb 27, 2020
Cited By (2)
US 12,357,965 US 12,466,875